<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844073</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MVC-101-01</org_study_id>
    <nct_id>NCT04844073</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer</brief_title>
  <official_title>A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA™) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),&#xD;
      pharmacodynamics and preliminary antitumor activity of MVC-101&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1/2, open-label study will characterize safety, dose-limiting toxicities (DLTs),&#xD;
      and maximum tolerated/ recommended phase 2 dose (MTD/RP2D) of MVC-101. Dose escalation will&#xD;
      occur in a 1+3 and then 3+3 design in patients with advanced solid tumors. Once the MTD/RP2D&#xD;
      is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and&#xD;
      initial anti-tumor activity in patients with HNSCC, CRC or NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>From time of study drug administration through the end of treatment or 28 days after the last dose of study drug</time_frame>
    <description>Based on signs, symptoms, physical examination findings and/or laboratory results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MVC-101 measured by plasma concentration of MVC-101</measure>
    <time_frame>Up to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MVC-101</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>Measured by plasma anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic anti-tumor activity</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>Assessed using both conventional Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and a modified RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>MVC-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD3 engaging conditionally active bispecific protein binding EGFR and CD3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVC-101</intervention_name>
    <description>CD3 engaging conditionally active bispecific protein binding EGFR and CD3</description>
    <arm_group_label>MVC-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Tumor histologies:&#xD;
&#xD;
               -  Dose Escalation: Patients with histologically proven, unresectable, locally&#xD;
                  advanced or metastatic solid cancers that are considered to express EGFR&#xD;
&#xD;
               -  Cohort Expansion:&#xD;
&#xD;
                    -  NSCLC that has progressed during or following treatment with platinum-based&#xD;
                       chemotherapy and an anti-PDx therapy NSCLC with EGFR mutation or ALK&#xD;
                       rearrangement must have progressed following available EGFR or ALK targeted&#xD;
                       therapy in addition to treatment with platinum-based chemotherapy&#xD;
&#xD;
                    -  HNSCC that has progressed during or following treatment with an anti-PDx&#xD;
                       (unless ineligible, e.g. patients failing chemotherapy and PD-L1 CPS &lt; 1)&#xD;
                       and platinum-based chemotherapy (unless ineligible/intolerant of&#xD;
                       platinum-based chemotherapy) for metastatic or recurrent disease&#xD;
&#xD;
                    -  CRC&#xD;
&#xD;
                         -  K-Ras WT: Patients who have progressed during or after, or are&#xD;
                            ineligible for, both irinotecan and oxaliplatin based chemotherapy and&#xD;
                            who are relapsed or refractory to at least 1 prior systemic therapy&#xD;
                            that included an anti-EGFR antibody&#xD;
&#xD;
                         -  K-Ras mutant: Patients who have progressed during or after, or are&#xD;
                            ineligible for, both irinotecan and oxaliplatin based chemotherapy&#xD;
&#xD;
          -  ECOG performance status of ≤ 1&#xD;
&#xD;
          -  Measurable disease as per RECIST v1.1 criteria and documented by CT and/or MRI&#xD;
&#xD;
          -  Patients must allow acquisition of existing archival tumor sample, either a block or&#xD;
             unstained slides.&#xD;
&#xD;
          -  Patients are required to consent for paired tumor biopsies: one in the screening&#xD;
             period and on during the first cycle of treatment&#xD;
&#xD;
          -  Acceptable laboratory parameters and adequate organ reserve&#xD;
&#xD;
          -  Patients who have previously received an immune checkpoint prior to enrollment must&#xD;
             have checkpoint inhibitor immune-related toxicity resolved to either Grade ≤ 1 or&#xD;
             baseline&#xD;
&#xD;
          -  Patients with symptomatic central nervous system metastases must have been treated, be&#xD;
             asymptomatic for ≥ 14 days, and must not have concurrent treatment or concurrent&#xD;
             leptomeningeal disease / cord compression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of known autoimmune disease with certain exceptions&#xD;
&#xD;
          -  Patients with clinically significant cardiovascular / vascular disease&#xD;
&#xD;
          -  Patients with clinically significant inflammatory gastrointestinal disorders&#xD;
&#xD;
          -  Patients with clinically significant pulmonary compromise&#xD;
&#xD;
          -  Major surgery or traumatic injury within 8 weeks from the date of first study dose&#xD;
&#xD;
          -  Unhealed wounds from surgery or injury&#xD;
&#xD;
          -  Treatment with radiation therapy &lt; 2 weeks from the date of first study dose&#xD;
&#xD;
          -  Inflammatory process that has not resolved for ≥ 4 weeks from the date of first study&#xD;
             dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientia Clinical Research Limited, Corner High &amp; Avoca Street, 5th Floor, Bright Building</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Lemech</last_name>
      <phone>Please contact</phone>
      <email>contactus@scientiaclinicalresearch.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Oncology Clinical Research Unit, 1 Flinders Drive</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganessan Kichenadasse</last_name>
      <phone>Please contact</phone>
      <email>clinicaltrials@socru.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health, Monash Medical Center, 246 Clayton Road</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophia Frentzas</last_name>
      <phone>Please contact</phone>
      <email>sophia.frentzas@monashhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre, Grattan Street, Parkville, Medical Oncology, Level 2</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathan Reader Wilson</last_name>
      <phone>Please contact</phone>
      <email>Pcctu.edd@petermac.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital, 145 Studley Road, Intensive Care Unit</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Weickhardt</last_name>
      <phone>Please contact</phone>
      <email>Andrew.WEICKHARDT@austin.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable locally advanced cancer</keyword>
  <keyword>Metastatic cancer</keyword>
  <keyword>EGFR expressing cancers</keyword>
  <keyword>EGFR</keyword>
  <keyword>CD3</keyword>
  <keyword>CD3-Bispecific</keyword>
  <keyword>Bispecific</keyword>
  <keyword>CRC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Squamous head and neck cancer</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

